SAB Biotherapeutics SABS Cash Flow Statement (2020-2026)

NASDAQ SABS
$3.11 +0.04 (+1.30%)
At close: Nov 11, 2026 · 4:00 PM EST
Reported Financials

SAB Biotherapeutics Quarterly Cash Flow Statement

Periods 24 quarters
Latest Sep 2026

SAB Biotherapeutics reported cash from operations of -$13.02M and free cash flow of -$14.37M for the quarter ended Sep 2026, up 0.2% year over year. This cash flow statement covers 24 quarters of results from Dec 2020 through Sep 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026 Sep2026
Operating Activities
Net Income
-11.55M0.99M-4.78M-7.08M-7.87M-7.35M-6.88M-5.10M-22.86M-5.03M-7.34M-10.35M-11.39M-5.20M-10.11M45.45M-16.86M-18.87M-22.49M-22.30M
Depreciation, Depletion & Amortization
Amortization of Deferred ChargesAmort. Deferred Charges
0.04M0.04M0.03M0.02M0.02M0.03M0.02M0.02M0.03M0.02M0.02M0.02M0.03M0.02M0.02M0.02M0.04M0.02M0.02M0.02M
Depreciation & Amortization (CF)Dep. & Amort.
0.62M0.64M0.75M0.89M0.93M0.90M0.90M1.00M0.97M2.00M1.00M0.90M0.76M0.80M0.80M0.70M0.70M0.73M0.80M0.80M
Share-based CompensationStock Comp.
0.65M0.90M0.57M0.58M0.63M0.60M0.64M0.64M1.99M0.62M0.60M1.05M0.67M0.61M0.63M0.80M3.17M5.46M7.25M7.44M
Gains from Sales and DivestituresGains Divest
0.01M0.00M12.000.02M-0.06M0.00M
Gains from Investment SecuritiesGains Investment
0.01M0.01M961.00-0.02M0.04M0.01M0.05M
Other non-cash itemsOther Non-Cash
4.32M-7.81M-1.73M-0.78M-0.07M-0.08M0.36M-0.18M8.13M-5.47M-2.22M-0.01M2.31M-5.04M0.63M-61.60M3.37M0.48M1.11M-1.65M
Change in Working Capital
Change in ReceivablesChange Receivables
-2.20M3.78M-2.17M3.33M-7.39M-4.79M-0.40M-0.36M
Change in Account PayablesChange Payables
0.34M0.52M-0.04M0.54M-1.81M-2.23M-0.04M-0.32M-0.11M0.24M-0.05M0.13M0.59M0.68M0.14M0.34M0.32M0.11M0.67M-2.21M
Change in Accrued ExpensesChange Accrued Exp.
0.28M-0.60M-2.00M0.38M-0.32M-1.73M-0.76M-0.63M1.40M-1.58M-0.07M1.86M-1.44M0.58M1.04M-0.29M-0.39M-1.19M1.83M4.31M
Change in TaxesChange Taxes
0.09M
Change in Other Operating AssetsOther Assets Change
1.61M0.37M-0.66M-0.86M0.42M-0.44M-0.21M-0.23M1.41M0.29M-0.69M0.03M0.96M0.29M0.26M-2.13M6.86M0.30M-1.19M0.00M
Change in Other Operating LiabilitiesOther Liabilities Change
-0.10M0.10M2.94M-0.04M-1.27M-0.31M-0.94M-0.26M-0.11M
Other Working Capital ChangesOther WC Changes
-1.61M-0.48M0.66M0.86M-0.32M3.38M0.17M0.13M-0.01M-0.01M-0.02M0.00M0.00M0.05M0.00M0.01M0.00M-0.07M-0.16M0.27M
Cash from OperationsCash from Ops.
-4.88M-9.54M-4.45M-7.92M-1.56M-1.61M-4.90M-5.17M-13.45M-10.75M-7.72M-6.29M-9.53M-7.80M-7.15M-13.05M-16.78M-14.27M-9.84M-13.02M
Investing Activities
Capital ExpendituresCapex
2.36M1.36M0.61M0.08M0.12M0.02M0.02M0.09M0.07M0.13M0.05M0.10M0.06M0.98M1.59M1.34M
Sales of Property, Plant and EquipmentPP&E (Sale)
0.08M0.04M500.00500.00-500.000.00M783.000.02M
Change in Property, Plant and EquipmentChange in PP&E
-2.36M-1.28M-0.61M-0.08M-0.12M-0.02M-0.02M-0.04M-0.07M-0.13M-0.05M-0.10M-0.06M500.00500.00-500.00-0.98M-1.58M-1.33M
Purchase of InvestmentsInvestments Purchased
-70.83M70.83M
Sale and Maturity of InvestmentsInvestments Sold
3.75M10.69M4.74M5.25M11.27M74.60M9.71M14.71M
Change in Acquisitions & DivestmentsChange Acquisitions
Cash from Investing ActivitiesCash from Investing
-2.36M-1.28M-0.61M-0.08M-0.12M-0.02M-0.02M-0.04M-0.07M-31.36M11.22M-1.15M9.33M4.67M5.20M-129.87M-1.71M-65.65M-4.88M6.07M
Financing Activities
Debt Issuance and Repayment
Long-Term Debt IssuancesLT Debt Issuance
-1.38M
Long-Term Debt RepaymentsLT Debt Repayment
1.15M0.80M0.80M0.29M3.79M0.36M0.36M0.14M0.29M0.25M0.25M0.65M0.27M0.03M0.31M0.04M0.04M0.04M
Net Long-Term Debt Issued (Repaid)Net LT Debt
-2.53M-0.80M-0.80M-0.29M-3.79M-0.36M-0.36M-0.14M-0.29M-0.25M-0.25M-0.65M-0.27M-0.03M-0.31M-0.04M-0.04M-0.04M
Net Debt Issuances and RepaymentsNet Debt Issuance
-2.53M-0.80M-0.80M-0.29M-3.79M-0.36M-0.36M-0.14M-0.29M-0.25M-0.25M-0.65M-0.27M-0.03M-0.31M-0.04M-0.04M-0.04M
Change in Capital Stock
Common Stock IssuedStock Issued
-117.63M0.01M0.07M1.007.68M0.00M0.00M59.66M0.02M-3.003.09M0.58M12.89M
Net Shares Issued and RepurchasedNet Shares Issued
-117.63M0.01M0.07M1.007.68M0.00M0.00M59.66M0.02M-3.003.09M0.58M12.89M
Net Equity Issued and RepurchasedNet Equity Issued
-117.63M0.01M0.07M1.007.68M0.00M0.00M59.66M0.02M-3.003.09M0.58M12.89M
Other financing activities (as filed)
6.55M-0.17M-0.07M-0.03M-0.05M0.00M-0.01M-0.02M-0.01M0.00M
Cash from Financing ActivitiesCash from Financing
36.03M-6.32M-0.73M-0.29M8.39M-0.36M-0.36M-0.14M67.64M-0.39M-0.32M-0.67M0.22M-0.17M-0.17M168.69M-0.04M89.92M2.36M13.00M
Additional items
Exchange Rate EffectFX Effect
-0.03M0.03M0.05M-0.29M0.04M0.18M-0.04M-0.40M0.01M0.11M0.12M
Change in Cash
28.79M-17.14M-5.79M-8.28M6.71M-1.99M-5.29M-5.35M54.14M-42.53M3.21M-8.07M-0.27M-3.26M-1.95M25.73M-18.92M10.02M-12.25M6.17M
Beginning Cash Balance
12.61M39.55M39.55M39.55M39.55M15.05M15.05M15.05M15.05M56.57M56.57M56.57M56.57M8.90M8.90M8.90M8.90M10.50M10.50M10.50M
Ending Cash Balance
39.55M22.41M16.62M8.33M15.05M13.06M7.77M2.43M56.57M14.03M17.24M9.17M8.90M5.64M3.69M29.43M10.50M20.52M8.27M14.44M
Free Cash FlowFCF
-7.24M-10.90M-5.06M-8.00M-1.67M-1.63M-4.92M-5.25M-13.51M-10.88M-7.77M-6.39M-9.59M-7.80M-7.15M-13.05M-16.78M-15.25M-11.43M-14.37M
Net Cash FlowNCF
28.79M-17.14M-5.79M-8.28M6.71M-1.99M-5.29M-5.35M54.12M-42.50M3.18M-8.12M0.02M-3.30M-2.13M25.77M-18.52M10.00M-12.36M6.05M
Interest Paid
0.07M0.07M0.07M0.15M0.08M0.04M0.06M0.07M0.07M0.08M0.15M0.07M0.07M0.06M0.04M0.06M0.06M0.06M0.06M
Income Taxes PaidTaxes Paid
0.24M-0.04M2.42M-191.00191.000.78M-143.00

SAB Biotherapeutics Cash Flow Statement API

Pull SAB Biotherapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=SABS&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY